Cenobamate for autoimmune epilepsy
Part of Brain & nervous system clinical trials.
This trial tests whether a new seizure medicine (cenobamate) helps people whose seizures are caused by an overactive immune system. You would stay on your current treatments and add cenobamate to see if it reduces seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with autoimmune epilepsy (seizures caused by your immune system).
- Your epilepsy medicines and immune therapies have been the same for the last 3 months.
- You do not have family short QT syndrome (a rare heart condition).
- You are not allergic to the study drug (cenobamate) and have no history of severe allergic skin reactions.
- You are not pregnant or breastfeeding, and can read and write in Italian.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a seizure medicine called cenobamate for people in the ICU who are having frequent seizures or a type of prolonged seizure called status epilepticus. It aims to see if this add-on treatment can help control seizures in this setting.
This study looks at how well cenobamate works when added to other seizure medications for adults with focal epilepsy. It uses real-world data from medical records to see how people respond to treatment.
This study looks at how cenobamate (a medication for seizures) affects healthcare use, like hospital visits or emergency room trips, in people with epilepsy whose seizures were not well-controlled by 2 to 5 other medicines. It is a real-world study, meaning it uses medical records to understand the impact.
This trial studies the safety of cenobamate for Japanese people who have partial onset seizures and have already finished a previous study of the same drug. It helps doctors learn more about long-term safety.
This study tests a new medicine (ONO-2017) for people with a type of epilepsy that causes whole-body seizures. It looks at whether adding this drug to your current seizure medicines can reduce how often those seizures happen.
This trial tests whether a drug called probenecid can help reduce the number of seizures that happen in a cluster during a hospital stay when your seizure medications are being reduced to record your seizures. The goal is to see if giving probenecid can make the monitoring period safer and more effective for people with focal epilepsy being evaluated for surgery.
Hear when a new Autoimmune Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.